BRPI0412472A - composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, métodos de tratamento e/ou prevenção de distúrbios lipìdicos (dislipidemia) associadas ou não com a resistência à insulina, e de aterosclerose, métodos de tratamento e/ou profilaxia de doença cardiovascular, de hipercolesterolemia, de condições associadas com a necessidade de se melhorar o transporte de colesterol reverso, e de se diminuir a absorção de colesterol no intestino, de de aumentar os nìveis de colesterol hdl, de se diminuir os nìveis de colesterol ldl, de condições inflamatórias, de mal de alzheimer, de arteriosclerose de diabetes tipo 2, de condições associadas com a necessidade de se melhorar a função de hdl, e, composição farmacêutica - Google Patents
composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, métodos de tratamento e/ou prevenção de distúrbios lipìdicos (dislipidemia) associadas ou não com a resistência à insulina, e de aterosclerose, métodos de tratamento e/ou profilaxia de doença cardiovascular, de hipercolesterolemia, de condições associadas com a necessidade de se melhorar o transporte de colesterol reverso, e de se diminuir a absorção de colesterol no intestino, de de aumentar os nìveis de colesterol hdl, de se diminuir os nìveis de colesterol ldl, de condições inflamatórias, de mal de alzheimer, de arteriosclerose de diabetes tipo 2, de condições associadas com a necessidade de se melhorar a função de hdl, e, composição farmacêuticaInfo
- Publication number
- BRPI0412472A BRPI0412472A BRPI0412472-3A BRPI0412472A BRPI0412472A BR PI0412472 A BRPI0412472 A BR PI0412472A BR PI0412472 A BRPI0412472 A BR PI0412472A BR PI0412472 A BRPI0412472 A BR PI0412472A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- methods
- need
- conditions
- improve
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 5
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 150000002632 lipids Chemical class 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 title abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 2
- 208000011775 arteriosclerosis disease Diseases 0.000 title abstract 2
- 230000004968 inflammatory condition Effects 0.000 title abstract 2
- 210000000936 intestine Anatomy 0.000 title abstract 2
- 230000004141 reverse cholesterol transport Effects 0.000 title abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 title 1
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 230000001906 cholesterol absorption Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 102000004311 liver X receptors Human genes 0.000 abstract 3
- 108090000865 liver X receptors Proteins 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 108091008039 hormone receptors Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
"COMPOSTO, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, FORMULAçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODOS DE TRATAMENTO E/OU PREVENçãO DE DISTúRBIOS LIPìDICOS (DISLIPIDEMIA) ASSOCIADAS OU NãO COM A RESISTêNCIA A INSULINA, E DE ATEROSCLEROSE, MéTODOS DE TRATAMENTO E/OU PROFILAXIA DE DOENçA CARDIOVASCULAR, DE HIPERCOLESTEROLEMIA, DE CONDIçõES ASSOCIADAS COM A NECESSIDADE DE SE MELHORAR O TRANSPORTE DE COLESTEROL REVERSO, E DE SE DIMINUIR A ABSORçãO DE COLESTEROL NO INTESTINO, DE SE AUMENTAR OS NìVEIS DE COLESTEROL HDL, DE SE DIMINUIR OS NìVEIS DE COLESTEROL LDL DE CONDIçõES INFLAMATóRIAS, DE MAL DE ALZHEIMER, DE ARTERIOSCLEROSE, DE DIABETES TIPO 2, DE CONDIçõES ASSOCIADAS COM A NECESSIDADE DE SE MELHORAR A FUNçãO DE HDL, E, COMPOSIçãO FARMACêUTICA". A invenção refere-se a certos novos compostos da Fórmula (I): a processos para prepará-los, à sua utilidade na modulação de receptores de hormónio nuclear Receptor X no Fígado (LXR) <244> (NR1H3) e/ou <225> (NR1H2) e no tratamento e/ou prevenção de condições clínicas incluindo doenças cardiovasculares, tais como aterosclerose; doenças inflamatórias, Mal de Alzheimer, distúrbios de lipídeos (dislipidemias) associadas ou não com resistência à insulina, diabetes tipo 2 e outras manifestações da síndrome metabólica, a métodos para seu uso terapêutico e a composições farmacêuticas os contendo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316232.8A GB0316232D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
| PCT/SE2004/001114 WO2005005417A1 (en) | 2003-07-11 | 2004-07-08 | Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412472A true BRPI0412472A (pt) | 2006-09-19 |
Family
ID=27741983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412472-3A BRPI0412472A (pt) | 2003-07-11 | 2004-07-08 | composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, métodos de tratamento e/ou prevenção de distúrbios lipìdicos (dislipidemia) associadas ou não com a resistência à insulina, e de aterosclerose, métodos de tratamento e/ou profilaxia de doença cardiovascular, de hipercolesterolemia, de condições associadas com a necessidade de se melhorar o transporte de colesterol reverso, e de se diminuir a absorção de colesterol no intestino, de de aumentar os nìveis de colesterol hdl, de se diminuir os nìveis de colesterol ldl, de condições inflamatórias, de mal de alzheimer, de arteriosclerose de diabetes tipo 2, de condições associadas com a necessidade de se melhorar a função de hdl, e, composição farmacêutica |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7432288B2 (pt) |
| EP (1) | EP1646626B1 (pt) |
| JP (1) | JP2007521312A (pt) |
| KR (1) | KR20060035748A (pt) |
| CN (1) | CN1823061A (pt) |
| AR (1) | AR045721A1 (pt) |
| AT (1) | ATE399777T1 (pt) |
| AU (1) | AU2004255999B2 (pt) |
| BR (1) | BRPI0412472A (pt) |
| CA (1) | CA2532056A1 (pt) |
| DE (1) | DE602004014773D1 (pt) |
| ES (1) | ES2308204T3 (pt) |
| GB (1) | GB0316232D0 (pt) |
| IL (1) | IL172760A0 (pt) |
| IS (1) | IS8293A (pt) |
| MX (1) | MXPA06000414A (pt) |
| MY (1) | MY135821A (pt) |
| NO (1) | NO20060081L (pt) |
| RU (1) | RU2006102130A (pt) |
| SA (1) | SA04250204B1 (pt) |
| TW (1) | TW200503691A (pt) |
| UA (1) | UA82109C2 (pt) |
| UY (1) | UY28408A1 (pt) |
| WO (1) | WO2005005417A1 (pt) |
| ZA (1) | ZA200600222B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1634877B1 (en) * | 2004-08-17 | 2011-06-22 | Simpson Biotech Co., Ltd. | Mixture and compounds from mycelia of antrodia camphorata and use thereof |
| US7505238B2 (en) * | 2005-01-07 | 2009-03-17 | Agnes Neves Woo | ESD configuration for low parasitic capacitance I/O |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| KR20070094963A (ko) | 2005-01-10 | 2007-09-27 | 아스트라제네카 아베 | 간 ｘ 수용체 조절제로서 이소티아졸-3(2ｈ)-온1,1-디옥사이드 유도체 |
| ES2433135T3 (es) * | 2006-04-28 | 2013-12-09 | Laboratorios Del Dr. Esteve, S.A. | Compuestos biciclicos de tetrahidropirrol |
| EP2069359B1 (en) | 2006-08-21 | 2014-11-12 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
| JP5615274B2 (ja) | 2008-07-01 | 2014-10-29 | ジェネンテック， インコーポレイテッド | Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法 |
| WO2010003025A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Bicyclic heterocycles as mek kinase inhibitors |
| CA2811145A1 (en) | 2010-09-07 | 2012-03-15 | Snu R&Db Foundation | Sesterterpene compound and use thereof |
| AU2011336970A1 (en) | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| WO2012074780A1 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
| EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
| US11648220B2 (en) | 2016-01-11 | 2023-05-16 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| EP4073025B1 (en) | 2019-12-13 | 2024-03-27 | Inspirna, Inc. | Metal salts and uses thereof |
| WO2022109066A1 (en) * | 2020-11-18 | 2022-05-27 | Southern Research Institute | Compounds for the treatment of acute and chronic kidney disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4929999A (en) | 1998-07-30 | 2000-02-21 | Japan Tobacco Inc. | Disubstituted maleimide compounds and medicinal utilization thereof |
| JP2002527419A (ja) * | 1998-10-08 | 2002-08-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類 |
| EP1212065A4 (en) * | 1999-07-08 | 2004-02-11 | Tularik Inc | COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL |
| EP1224932A4 (en) | 1999-08-20 | 2002-10-16 | Sagami Chem Res | ACTIVE SUBSTANCES TO INHIBIT CELL DEATH |
| GB0008264D0 (en) | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
-
2003
- 2003-07-11 GB GBGB0316232.8A patent/GB0316232D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119064A patent/TW200503691A/zh unknown
- 2004-07-05 SA SA4250204A patent/SA04250204B1/ar unknown
- 2004-07-08 CN CNA2004800198411A patent/CN1823061A/zh active Pending
- 2004-07-08 AU AU2004255999A patent/AU2004255999B2/en not_active Ceased
- 2004-07-08 KR KR1020067000712A patent/KR20060035748A/ko not_active Withdrawn
- 2004-07-08 DE DE602004014773T patent/DE602004014773D1/de not_active Expired - Fee Related
- 2004-07-08 EP EP04749150A patent/EP1646626B1/en not_active Expired - Lifetime
- 2004-07-08 US US10/564,235 patent/US7432288B2/en not_active Expired - Fee Related
- 2004-07-08 MX MXPA06000414A patent/MXPA06000414A/es not_active Application Discontinuation
- 2004-07-08 ES ES04749150T patent/ES2308204T3/es not_active Expired - Lifetime
- 2004-07-08 WO PCT/SE2004/001114 patent/WO2005005417A1/en not_active Ceased
- 2004-07-08 AT AT04749150T patent/ATE399777T1/de not_active IP Right Cessation
- 2004-07-08 AR ARP040102419A patent/AR045721A1/es not_active Application Discontinuation
- 2004-07-08 BR BRPI0412472-3A patent/BRPI0412472A/pt not_active IP Right Cessation
- 2004-07-08 CA CA002532056A patent/CA2532056A1/en not_active Abandoned
- 2004-07-08 JP JP2006520138A patent/JP2007521312A/ja not_active Withdrawn
- 2004-07-08 RU RU2006102130/04A patent/RU2006102130A/ru not_active Application Discontinuation
- 2004-07-09 UY UY28408A patent/UY28408A1/es unknown
- 2004-07-09 MY MYPI20042745A patent/MY135821A/en unknown
- 2004-08-07 UA UAA200600272A patent/UA82109C2/uk unknown
-
2005
- 2005-12-22 IL IL172760A patent/IL172760A0/en unknown
-
2006
- 2006-01-05 NO NO20060081A patent/NO20060081L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600222A patent/ZA200600222B/en unknown
- 2006-02-09 IS IS8293A patent/IS8293A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004255999B2 (en) | 2007-08-02 |
| IL172760A0 (en) | 2006-04-10 |
| NO20060081L (no) | 2006-02-08 |
| ZA200600222B (en) | 2007-04-25 |
| TW200503691A (en) | 2005-02-01 |
| WO2005005417A1 (en) | 2005-01-20 |
| CN1823061A (zh) | 2006-08-23 |
| UY28408A1 (es) | 2005-02-28 |
| MXPA06000414A (es) | 2006-03-17 |
| AR045721A1 (es) | 2005-11-09 |
| SA04250204B1 (ar) | 2008-03-23 |
| EP1646626A1 (en) | 2006-04-19 |
| UA82109C2 (uk) | 2008-03-11 |
| US20060235015A1 (en) | 2006-10-19 |
| ES2308204T3 (es) | 2008-12-01 |
| EP1646626B1 (en) | 2008-07-02 |
| RU2006102130A (ru) | 2007-08-20 |
| IS8293A (is) | 2006-02-09 |
| US7432288B2 (en) | 2008-10-07 |
| HK1088320A1 (en) | 2006-11-03 |
| DE602004014773D1 (de) | 2008-08-14 |
| ATE399777T1 (de) | 2008-07-15 |
| KR20060035748A (ko) | 2006-04-26 |
| CA2532056A1 (en) | 2005-01-20 |
| AU2004255999A1 (en) | 2005-01-20 |
| MY135821A (en) | 2008-07-31 |
| JP2007521312A (ja) | 2007-08-02 |
| GB0316232D0 (en) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0412479A (pt) | composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, métodos de tratamento e/ou prevenção de distúrbios lipìdicos (dislipidemia) associados ou não com a resistência à insulina, e de aterosclerose, e, métodos de tratamento e/ou profilaxia de doença cardiovascular, de hipercolesterolemia, condições associadas com a necessidade de se melhorar o transporte de colesterol reverso, de se diminuir a absorção de colesterol no intestino, de se aumentar os nìveis de colesterol hdl, de se diminuir os nìveis de colesterol ldl, de condições inflamatórias, de mal de alzheimer, de arteriosclerose, de diabetes tipo 2, e de condições associadas com a necessidade de se melhorar a função de hdl, e, composição farmacêutica | |
| BR0111908A (pt) | Composto, composição farmacêutica, uso do composto, e, método para o tratamento e/ou prevenção de distúrbios ou doenças | |
| BR0211665A (pt) | Composto, composição farmacêutica, método para a redução de glicose, método para a prevenção ou para tratamento de doenças, medicamento para a redução de glicose, medicamento para a prevenção ou para o tratamento de doenças, uso do composto, da composição farmacêutica e do medicamento e processo para a preparação do composto | |
| BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
| BR0209957A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
| BR0214988A (pt) | S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| AU2005309586A1 (en) | Capsaicinoid gel formulation and uses thereof | |
| BR0207910A (pt) | HidantÈnios e sua utilização no tratamento do diabetes | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BR0315720A (pt) | Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário | |
| TW200503691A (en) | Therapeutic agents | |
| NO20073250L (no) | Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser. | |
| BR0317458A (pt) | EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| BR0307441A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade | |
| BR0016135A (pt) | Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto | |
| BR0016131A (pt) | Forma cristalina, formulação farmacêutica, uso de uma forma cristalina, uso de uma substância, métodos para tratamento ou a profilaxia de, condições associadas com reduzida sensibilidade à insulina, e de deslipidemia, diabetes melito do tipo 2, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal, e , processo para a preparação de uma forma cristalina de um composto de fórmula i | |
| BR9902808A (pt) | Compostos, composição farmacêutica, composição cosmética e uso de uma composição cosmética | |
| DE69333387D1 (de) | Pharmazeutische Zusammensetzungen enthaltend Norastemizol. | |
| NO20073248L (no) | Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer | |
| BR0318242A (pt) | derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação | |
| BR0309896A (pt) | Compostos, uso em um composto, composição farmacêutica, composição cosmética, uso cosmético de uma composição | |
| SE0500056D0 (sv) | Therapeutic agents 4 | |
| BR0105787A (pt) | Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico | |
| BR0215090A (pt) | Composto, enanciÈmero (r) ou enanciÈmero (s) de um composto, formulação farmacêutica, método para tratar ou prevenir distúrbios lipìdicos (dislipidemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou prevenir diabetes de tipo 2, processo para preparar um composto, e, composição farmacêutica | |
| BR0312461A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e métodos para tratamento e profilaxia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |